GlassScriptPhysician profile
Zachary A King
NPI 1144503517
$1,711.46
in general payments reported to CMS, 2019-2025
30 companies · $524 in 2025
The $524 reported for 2025 was more than what 91% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $29.77 · 2021: $201 · 2022: $114 · 2023: $416 · 2024: $307 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,246.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $213.85 | 2019-2025 | |
| Abbvie INC. | $208.54 | 2021-2025 | |
| Kerecis Limited | $172.29 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Scilex Pharmaceuticals INC. | $161.08 | 2023-2024 | Ztlido |
| Abbott Laboratories | $147.58 | 2020-2024 | Proclaim |
| Averitas Pharma INC. | $84.97 | 2023 | Qutenza |
| Biohaven Pharmaceutical Holding Company LTD. | $81.66 | 2022 | |
| Spr Therapeutics, INC | $77.71 | 2024-2025 | Sprint Pns System |
| Bioventus LLC | $71.23 | 2023-2025 | Xcell, Durolane, Supartz Fx Sodium Hyaluronate |
| Nevro Corp. | $49.66 | 2021-2024 | Senza |
| Saluda Medical Americas, INC. | $45.09 | 2024-2025 | Evoke |
| Tonix Medicines, INC. | $42.06 | 2025 | Tonmya |
| Collegium Pharmaceutical, INC. | $34.20 | 2025 | Belbuca |
| Amgen INC. | $34.01 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $29.74 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28.11 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Novartis Pharmaceuticals Corporation | $24.02 | 2021 | |
| Si-Bone, INC. | $21.41 | 2025 | |
| Nalu Medical, INC. | $20.81 | 2023 | Nalu Neurostimulation System |
| Orthogenrx INC. | $18.45 | 2019 | |
| Vertos Medical, INC. | $18.36 | 2023 | Mild Device Kit |
| Novo Nordisk INC | $16.32 | 2021 | |
| Dexcom, INC. | $15.77 | 2021 | |
| Medtronic USA, INC. | $15.27 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.23 | 2019 | |
| Abiomed | $13.75 | 2024 | Impella |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.72 | 2021 | |
| Grt US Holding, INC. | $13.62 | 2021 | |
| Allergan, INC. | $12.16 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.